The Clinical Manifestations of the Severe Acute Respiratory Syndrome, Coronavirus 2( SARS-Cov-2 ); Not Only Pulmonary

Study Overview
=================
Brief Summary
-----------------
A prospective observational study to identify different extrapulmonary clinical manifestations of SARS-CoV-2 and its correlations with the disease severity grades.

Detailed Description
-----------------
The current research in this area was retrospective trials; this study is a prospective one. Investigators will perform the extensive recording of extrapulmonary manifestations in adult patients of SARS-CoV-2 and their correlations with the disease severity grades. Type of the study: a prospective observational study Study Setting: Data will be collected from outpatients and inpatients files and a questionnaire. Sample Size Calculation: Depending on the average monthly (40-50 cases) and type of the study : -Investigators will use Steven K. Thompson equation 13 to calculate the size from the next formula Population size =(752) Sample size = (414) Level of confidence: ( 95%) Error proportion: (0.05) Probability :(20 %) Study power: (80 %)

Official Title
-----------------
The Clinical Manifestations of SARS-Cov-2 Disease; Not Only Pulmonary

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients have been confirmed diagnosed with Covid-19 disease by PCR Patients aged 18 years and above Exclusion Criteria: Patients aged below 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID_Patients<br>Patients have been confirmed diagnosed with Covid-19 disease by PCR Patients aged 18 years and above | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who has one or more of the following extrapulmonary clinical manifestations of SARS-CoV-2 . | Cardiovascular : Coronary Artery Disease Infarction (type 2) Myocarditis Arrhythmia Cardiogenic shock Heart failure Gastrointestinal : Anorexia Diarrhea Bleeding Digestive symptoms Abnormal liver tests Neurological : Headache Impaired consciousness acute ischemic stroke Ataxia Dizziness Seizure Taste impairment Smell impairment Vision impairment Viral encephalitis Depression Endocrinal: Hypoglycemia Ketoacidosis Hyperglycemia Thyrotoxicosis Secondary Adrenal Insufficiency Hematological: Leukocytosis Leukopenia Thrombocytopenia Anemia Lymphocytosis D-dimer Lactate dehydrogenase Ferritin Renal : Albuminuria Hematuria Blood urea nitrogen Acute kidney injury Ophthalmologic : -Conjunctivitis Dermatologic : Papulovesicular rash Rosacea Dryness Erythema Urticaria Maculopapular exanthem morbilliform | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The correlations between the number of participants who has extrapulmonary manifestations and the severity grade of SARS-CoV-2. | These correlations between the number of participants who has one or more of extrapulmonary manifestations and the severity of SARS-CoV-2, will be measured. There are four severity grades of SARS-CoV-2 according to WHO classifications (mild, moderate, severe and critical) | one year |